Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors.
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings and welcome to the Delcath Systems' Third Quarter 2024 Earnings Call.
Delcath Systems, Inc. (DCTH) Reports Q3 Loss
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.
Delcath Is On Schedule For A Monster 2025: A Platform Valuation Awaits
Delcath's HEPZATO KIT launch is gaining momentum, setting the company up for a strong 2025. My 2025 sales target is about double the consensus. The stock corrected after the Q2 report due to slower-than-expected hospital formulary acceptances, but Delcath is on track to reach 22 active centers in Q1 2025. ICC and mCRC are the next indications that will cement PHP's position as a platform technology. This will increase Delcath stock's multiple.
Delcath Systems Inc (DCTH) Q2 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants John Newman - Canaccord Genuity Corp Marie Thibault - BTIG Swayampakula Ramakanth - H.C. Wainwright Sudan Loganathan - Stephens Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to Delcath Systems' Second Quarter 2024 Earnings Conference Call.
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.58 per share a year ago.
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
